LoQus23 moves Huntington’s disease candidate into development
UK-based biotech LoQus23 Therapeutics is advancing an oral small molecule targeting a fundamental genetic process in Huntington’s disease, a rare neurodegenerative disorder.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1405 entries already.
Entries by Thomas Gabrielczyk
With Vyvgart established, argenx looks beyond its founder CEO
/in News/by Thomas GabrielczykThe Dutch biotech argenx has announced a planned leadership transition to be effective in May after its annual shareholder meeting. Tim Van Hauwermeiren, co-founder and long-time Chief Executive Officer, will transition from CEO to Non-Executive Director and Chairman of the Board of Directors; and Karen Massey, currently Chief Operating Officer, will assume the role of CEO and Executive Director, pending shareholder approval.
Servier and Insilico sign an $888 million AI oncology discovery deal
/in News/by Thomas GabrielczykOn January 4, the French pharma group Servier and the AI drug discovery Insilico Medicine announced a collaboration worth up to $888 million. Insilico will receive up to $32 million from Servier for a multi-year research and development collaboration to discover and develop oncology therapies using Insilico’s artificial intelligence (AI)-driven drug discovery platform and Servier’s cancer development expertise.
FDA approves globally first obesity pill
/in News/by Thomas GabrielczykFDA approves Novo Nordisk’s first oral GLP-1 pill Wegovy for obesity, offering an injection-free option and improving long-term treatment adherence.
Nine Big Pharma to cut US drug prices in Most-favoured Nations deals
/in News/by Thomas GabrielczykNine pharma giants will cut US drug prices up to 90 % via TrumpRx and direct channels, following previous Pfizer and AstraZeneca MFN deals.
Trump Administration tables new version of Biosecure Act
/in News/by Thomas GabrielczykThe Trump administration has tabled a new Biosecure Act, prompting industry concern over oversight shift, regulatory uncertainty and need for stronger US biotech strategy.
EU committee approves New Plant Breeding (NGT) techniques
/in News/by Thomas GabrielczykOn Friday, the EU committee of Permanent Representatives of EU Member States backed the deregulation of new genomic plant breeding techniques, easing regulation for NGT1 crops.
Egetis Therapeutics AB submits rolling NDA for tiratricol
/in News/by Thomas GabrielczykEgetis Therapeutics has submitted a rolling NDA for Tiratricol to treat rare MCT8 transporter deficiency. The application for priority review is based on positive ReTRIACt study results.
FoRx raises US$50m in Series A to advance PARG inhibitor
/in News/by Thomas GabrielczykSwiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026.
Belgian microbiome player MRM Health initiates R&D partnership in cancer immunotherapy
/in News/by Thomas GabrielczykFollowing a €55m (US$64m) Series B financing in September, Ghent-based MRM Health today announced a strategic collaboration with the research group of Professor Emile Voest, Senior Group Leader at the Netherlands Cancer Institute (NKI) and Senior Investigator at Oncode Institute.